KVP Capital Advisors, LP

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), KVP Capital Advisors, LP reported 35 stock positions worth $136.2 million. Its top holding was Praxis Precision Medicines I (PRAX) at 10.5% of the portfolio, followed by Whitehawk Therapeutics (WHWK, 7.3%) and Erasca (ERAS, 6.1%). Compared with Q1 2026, it opened 6 new positions, sold out of 3, added to 2 and reduced 2. The biggest buy was a new position in Tandem Diabetes Care (TNDM) and the biggest sale an exit from Terns Pharmaceuticals (TERN).

Most Recent 13F
Q2 2026
Location
SAN FRANCISCO, CA
CIK
0001858198
Portfolio Value
$136.2M (Q2 2026)
SEC Filing
0001104659-26-095988 ↗ filed Aug 13, 2026

Holdings Value

0$50.0M$100.0M$150.0M Q4 2025: $96.8M Q4 2025 Q1 2026: $133.9M Q1 2026 Q2 2026: $136.2M $136.2M Q2 2026

Holdings 35 stocks · $136.2M
PRAX Praxis Precision Medicines I 10.54% 42,900 $14.4M No change
WHWK Whitehawk Therapeutics Inc. 7.28% 2,165,997 $9.9M No change
ERAS Erasca Inc. 6.12% 455,000 $8.3M Add +33.8%
TRVI Trevi Therapeutics Inc. 5.67% 414,000 $7.7M No change
STRO Sutro Biopharma Inc. 5.52% 226,575 $7.5M No change
TNGX Tango Therapeutics Inc. 5.28% 230,264 $7.2M No change
MBX MBX Biosciences Inc. 4.92% 121,524 $6.7M No change
PTGX Protagonist Therapeutics Inc. 4.77% 53,000 $6.5M No change
EWTX Edgewise Therapeutics Inc. 3.97% 133,000 $5.4M No change
TNDM Tandem Diabetes Care Inc. 3.33% 301,000 $4.5M New
IRON Disc Medicine Inc. 3.13% 58,250 $4.3M No change
SVRA Savara Inc. 2.74% 605,280 $3.7M No change
AVBP Arrivent Biopharma Inc. 2.60% 102,000 $3.5M New
INSM Insmed Inc. 2.23% 28,497 $3.0M No change
ACHV Achieve Life Sciences Inc. 2.22% 462,355 $3.0M No change
IDYA Ideaya Biosciences Inc. 2.18% 79,700 $3.0M No change
OCUL Ocular Therapeutix Inc. 2.16% 300,000 $2.9M No change
AXSM Axsome Therapeutics Inc. 2.16% 12,000 $2.9M Reduce -66.8%
DSGN Design Therapeutics Inc. 1.96% 185,000 $2.7M New
UTHR United Therapeutics Corp. 1.89% 4,750 $2.6M No change
SRRK Scholar Rock Holding Corp. 1.82% 45,000 $2.5M No change
IMMX Immix Biopharma Inc. 1.74% 230,423 $2.4M No change
VRDN Viridian Therapeutics Inc. 1.69% 125,000 $2.3M No change
MLYS Mineralys Therapeutics Inc. 1.67% 84,168 $2.3M New
DRUG Bright Minds Biosciences Inc. 1.64% 31,813 $2.2M No change
TVTX Travere Therapeutics Inc. 1.63% 39,000 $2.2M Reduce -57.1%
ZURA Zura Bio Ltd. 1.62% 373,128 $2.2M No change
ARTV Artiva Biotherapeutics Inc. 1.42% 200,000 $1.9M New
NKTR Nektar Therapeutics 1.38% 26,900 $1.9M No change
CMPX Compass Therapeutics Inc. 1.24% 771,000 $1.7M Add +54.2%
CABA Cabaletta Bio Inc. 1.15% 505,431 $1.6M No change
VERA Vera Therapeutics Inc. 1.03% 32,700 $1.4M No change
EOLS Evolus Inc. 0.76% 150,000 $1.0M New
CELC Celcuity Inc. 0.31% 4,000 $418K No change
VYNE THERAPEUTICS INC 0.24% 500,551 $326K No change

Portfolio Sells Q1 2026 → Q2 2026
TERN Terns Pharmaceuticals Inc. Sold out 0.00% −17.32
RVMD Revolution Medicines Inc. Sold out 0.00% −2.92
AXSM Axsome Therapeutics Inc. Reduce -66.8% 2.16% −2.41
SLNO Soleno Therapeutics Inc. Sold out 0.00% −1.49
TVTX Travere Therapeutics Inc. Reduce -57.1% 1.63% −0.39

Portfolio Buys Q1 2026 → Q2 2026
TNDM Tandem Diabetes Care Inc. New 3.33% +3.33
AVBP Arrivent Biopharma Inc. New 2.60% +2.60
ERAS Erasca Inc. Add +33.8% 6.12% +2.01
DSGN Design Therapeutics Inc. New 1.96% +1.96
MLYS Mineralys Therapeutics Inc. New 1.67% +1.67
ARTV Artiva Biotherapeutics Inc. New 1.42% +1.42
EOLS Evolus Inc. New 0.76% +0.76
CMPX Compass Therapeutics Inc. Add +54.2% 1.24% −0.74

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 35$136.2MPRAX, WHWK, ERAS, TRVI, STRO
Q1 2026 32$133.9MTERN, PRAX, WHWK, AXSM, STRO
Q4 2025 25$96.8MTERN, PRAX, AXSM, WHWK, TRVI